These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18505898)

  • 21. Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma.
    Ikeda O; Tamura Y; Nakasone Y; Shiraishi S; Kawanaka K; Tomiguchi S; Yamashita Y; Takamori H; Kanemitsu K; Baba H
    Cardiovasc Intervent Radiol; 2007; 30(5):912-21. PubMed ID: 17710478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
    Hess V; Pratsch S; Potthast S; Lee L; Winterhalder R; Widmer L; Cescato C; Lohri A; Jost L; Stillhart P; Pestalozzi B; Herrmann R
    Ann Oncol; 2010 Dec; 21(12):2390-2395. PubMed ID: 20444846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
    Honda K; Fukuhara T; Kojima Y; Tanaka H; Kushihata F; Kobayashi N
    Gan To Kagaku Ryoho; 2006 Dec; 33(13):2089-92. PubMed ID: 17197760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX.
    Fogelman DR; Chen J; Chabot JA; Allendorf JD; Schrope BA; Ennis RD; Schreibman SM; Fine RL
    Surg Oncol Clin N Am; 2004 Oct; 13(4):711-35, x. PubMed ID: 15350944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
    Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
    Chung KH; Ryu JK; Son JH; Lee JW; Jang DK; Lee SH; Kim YT
    Gut Liver; 2017 Mar; 11(2):298-305. PubMed ID: 27965478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
    Francois E; Bennouna J; Chamorey E; Etienne-Grimaldi MC; Renée N; Senellart H; Michel C; Follana P; Mari V; Douillard JY; Milano G
    Chemotherapy; 2012; 58(5):371-80. PubMed ID: 23235319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
    Kim ST; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Heo JS; Choi SH; Choi DW; Park YS; Lim HY; Kang WK; Jang KT; Park HC; Lim DH; Park JO
    Am J Clin Oncol; 2012 Oct; 35(5):432-8. PubMed ID: 21606820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.
    Song HS; Do YR; Chang HM; Ryu MH; Lee KH; Kim YH; Hong DS; Cho JY; Lee KE; Kim SY
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):763-8. PubMed ID: 18172648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
    Heinemann V; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler TC; von Weikersthal LF; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Rubanov O; Baake G; Höhler T; Ko YD; Jung A; Neugebauer S; Boeck S
    Gut; 2013 May; 62(5):751-9. PubMed ID: 22773551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
    Soares HP; Bayraktar S; Blaya M; Lopes G; Merchan J; Macintyre J; Mayo C; Green MR; Silva O; Levi J; Walker G; Rocha-Lima CM
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):839-45. PubMed ID: 24562589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma.
    Yuan Y; Shen H; Hu XY; Gu FY; Li MD; Zhong X
    Med Oncol; 2012 Jun; 29(2):957-61. PubMed ID: 21387165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival for patients with pancreatic cancer after addition of gemcitabine to Fluorouracil chemoradiation.
    Fujita T
    JAMA; 2008 Jun; 299(24):2852; author reply 2852-3. PubMed ID: 18577725
    [No Abstract]   [Full Text] [Related]  

  • 35. Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
    Xenidis N; Chelis L; Amarantidis K; Chamalidou E; Dimopoulos P; Courcoutsakis N; Tentes A; Chiotis A; Prassopoulos P; Kakolyris S
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):477-84. PubMed ID: 21858532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
    Zafar SF; El-Rayes BF
    Am J Clin Oncol; 2014 Apr; 37(2):194-200. PubMed ID: 22643564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
    Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
    Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase I study.
    Mambrini A; Pacetti P; Del Freo A; Seta RD; Pezzuolo D; Torri T; Orlandi M; Tartarini R; Cantore M
    Anticancer Res; 2009 May; 29(5):1547-9. PubMed ID: 19443364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
    Saif MW; Syrigos K; Penney R; Kaley K
    Anticancer Res; 2010 Jul; 30(7):2905-9. PubMed ID: 20683031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.